Last issue we made the case that vitiligo is an autoimmune disease with an approved therapy, not a cosmetic finding: confirm before labeling, check the thyroid, match treatment to site, and set the timeline.

This week we stay with autoimmune skin disease that hides behind a more familiar word. Everyone knows what hives are. And that familiarity is the problem.

A patient has had daily hives for four months. Somewhere in there they have accumulated an IgE panel, a food allergy workup, an elimination diet that removed dairy and then gluten and then tomatoes, and three prednisone bursts. The hives are unchanged.

The patient is now convinced there is an allergen no one has found yet, and every visit reinforces that theory.

Chronic spontaneous urticaria is not an allergic process in most patients, and the search for the trigger is usually the reason effective treatment gets delayed by months.

The definitions are worth stating cleanly.

Urticaria becomes chronic at 6 weeks. It divides into spontaneous disease, which has no external trigger, and inducible disease, which is reproduced by a physical stimulus like pressure, cold, heat, sweating, vibration, or water.

Chronic spontaneous urticaria affects roughly 1% of people, typically runs 1 to 5 years, and persists beyond 5 years in about 20% of patients.

Roughly half of patients are not controlled by antihistamines regardless of how far the dose is escalated.

That last number used to be the end of the conversation in primary care. It is not anymore.

The mistake: Ordering an IgE panel, a food allergy workup, or a broad autoimmune screen because hives must be a reaction to something.

Why it happens: The word "allergy" is built into how patients and clinicians both talk about hives, and a negative panel feels like progress.

The evidence: Chronic spontaneous urticaria is mast cell driven and, in a substantial share of patients, autoimmune. Skin testing for allergens is not standard of care in chronic urticaria, and extensive routine testing does not improve outcomes or prove cost-effective (World Allergy Organization Journal, 2025). The international guideline recommends against routine testing in acute urticaria, and for chronic spontaneous disease recommends limited investigation only: a differential blood count plus CRP or ESR. The AAAAI practice parameter adds liver enzymes and TSH to that short list. For chronic inducible urticaria, the diagnostic test is provocation with the suspected physical stimulus, not a serum panel.

Practical tip: Take the history that actually sorts this. Ask whether lesions follow pressure, cold, heat, exercise, sweating, vibration, or water contact, because that answer moves the patient into the inducible column and changes the workup entirely. Order the short list: CBC with differential, CRP or ESR, and TSH if the picture supports it. Then say the sentence out loud, because no one has said it yet: we are not going to find a food that is causing this, and that is not a failure of testing.

The mistake: Standard-dose cetirizine taken as needed, no improvement, and a note that antihistamines did not work.

Why it happens: The over-the-counter label sets the anchor at one tablet, and patients take them the way they take ibuprofen, reactively.

The evidence: Second-generation H1 antihistamines are first-line, taken daily rather than as needed, and guidelines recommend increasing the dose up to fourfold in patients who remain symptomatic. Studies of updosing have generally not shown a dose-dependent increase in adverse effects, and patient-reported data support both greater effectiveness and better tolerability of second-generation agents versus first-generation ones at higher doses (PLoS One, 2011; updosing reviews). Guidelines explicitly advise against first-generation sedating antihistamines as first-choice therapy. Even so, every third to fourth patient remains symptomatic after fourfold dosing, and prolonged ineffective antihistamine therapy should be avoided because it delays disease control.

Practical tip: Prescribe it as a scheduled daily medication and escalate deliberately. Same agent, up to four times the standard dose, reassessed at 2 to 4 weeks. Give "failed" a definition by tracking itch and hive counts, ideally a UAS7. If fourfold dosing for 2 to 4 weeks has not controlled the disease, that is the signal to step up rather than to keep waiting.

The mistake: Another steroid burst, then another, as the recurring answer to a chronic disease.

Why it happens: It works within days, the patient is miserable, and it feels like doing something decisive.

The evidence: Short corticosteroid courses have a place in severe exacerbations, but the guideline algorithm moves from second-generation antihistamine to updosing to step-up therapy. It does not include serial steroid bursts, and each repeat course adds cumulative risk while the underlying disease goes untreated. In practice, repeated bursts function as a substitute for escalation and push effective therapy further away.

Practical tip: Put a ceiling on it in your own head. More than one short course in a year is a referral trigger, not a refill. If the patient is asking for prednisone because the hives always come back, that request is the clinical information: the current regimen is not adequate and the next rung is where the visit should go.

The mistake: Treating every wheal as urticaria without checking the features that separate it from vasculitis, bradykinin-mediated angioedema, or anaphylaxis.

Why it happens: They all look like hives at the door, and the differentiating features are historical rather than visual.

The evidence: Individual urticarial wheals are transient and resolve within 24 hours in a fixed location. Lesions that persist beyond 24 hours, burn or hurt rather than itch, or leave bruising or hyperpigmentation as they fade suggest urticarial vasculitis, particularly alongside fever, arthralgia, or systemic symptoms, and that presentation warrants a punch biopsy (DermNet; urticarial vasculitis reviews). Angioedema without wheals raises bradykinin-mediated disease, including ACE inhibitor angioedema and hereditary angioedema, which does not respond to antihistamines or corticosteroids. That label is also overapplied: up to 10% of chronic spontaneous urticaria presents as isolated angioedema, and in a referral cohort of patients sent for presumed ACE inhibitor angioedema, 41% were ultimately reclassified as mast cell driven. Antihistamine non-response alone does not settle the question. And urticaria accompanied by respiratory or cardiovascular compromise is anaphylaxis, where epinephrine is the treatment and antihistamines are adjunctive.

Practical tip: Hand the patient a pen. Ask them to circle one lesion and photograph it, then check the same spot at 24 hours. That single instruction separates urticaria from urticarial vasculitis more reliably than any lab you can order at the first visit.

The mistake: Cycling antihistamines and steroids indefinitely without a referral, and sending the patient home with no sense of the disease course.

Why it happens: Step-up therapy used to mean one drug, often with a difficult authorization, so the threshold to pursue it stayed high.

The evidence: The landscape moved fast. Omalizumab still has the deepest evidence base, with 34% to 44% of patients achieving complete control at week 12 across the ASTERIA I, ASTERIA II, and GLACIAL trials, and a network meta-analysis continues to rank it first among biologic options (J Dermatolog Treat, 2025). Dupilumab was approved in April 2025 for patients 12 and older with CSU symptomatic despite H1 antihistamines, the first new targeted therapy for the disease in over a decade, and that indication was extended in April 2026 to children aged 2 to 11. Remibrutinib, an oral BTK inhibitor, was approved in September 2025 for adults who remain symptomatic on antihistamines. The 2026 update to the international urticaria guideline names dupilumab and remibrutinib alongside omalizumab as step-up options after antihistamine failure, the most substantive change to the algorithm in years. Natural history matters too: most chronic spontaneous urticaria runs 1 to 5 years, with roughly 20% persisting beyond 5 years.

Practical tip: Give patients the two facts they almost never receive. This is not an allergy, and it usually resolves, but on the order of years rather than weeks. Then name the referral threshold in the same breath: uncontrolled disease after 2 to 4 weeks of fourfold antihistamine dosing means it is time for allergy or dermatology, and an oral step-up option now exists for patients who will not accept an injectable.

Hives generate a large volume of primary care and urgent care visits, and mismanagement here is unusually expensive in both money and time. Allergy panels and elimination diets cost real dollars and produce no yield in a disease that is not allergen driven, while the patient spends months believing the answer is one more test away.

The quality-of-life cost is easy to underestimate because the disease is neither disfiguring nor fatal. Impairment in chronic urticaria has been compared to that of ischemic heart disease, driven by relentless itch, disrupted sleep, and the unpredictability of not knowing which morning brings hives.

Primary care controls the two decisions that matter most here: whether the patient spends four months hunting a trigger, and whether antihistamines get dosed to the point where "failed" actually means something. Both of those happen before a specialist ever sees the chart.

Skip the allergen hunt. History plus a differential blood count and CRP or ESR, with TSH where the picture supports it. No IgE panels, no elimination diets, no shotgun autoimmune screens.

Ask about physical triggers first. Pressure, cold, heat, sweating, vibration, and water separate inducible from spontaneous disease and change the whole workup.

Dose the antihistamine like you mean it. Second generation, daily rather than as needed, escalated up to fourfold, reassessed at 2 to 4 weeks.

Cap the steroids and use the request as data. More than one short course a year is a referral trigger, not a refill.

Know the 24-hour rule and the new ladder. Wheals lasting past 24 hours, burning, or bruising means biopsy for vasculitis. Angioedema without wheals means think bradykinin. And uncontrolled disease on maximal antihistamines now has three step-up options, including an oral one.

Interested in reaching our 8,000+ subscribers?

Click here to learn more!

https://go.dermforprimarycare.com/newsletter-sponsor-lp 

We have created this FREE Guide for you:

Hives are a good reminder that a familiar word can carry an inaccurate model. Patients arrive certain they have an allergy, and the workup we order to reassure them tends to confirm the belief that the answer has simply not been found yet.

Name the disease accurately, dose the first-line drug to the point where failure means something, keep the 24-hour rule in your pocket, and refer when the ladder runs out.

That turns a recurring frustration visit into a treatment plan with a defined next step 🧑‍⚕

Have a topic you'd like us to cover? Reply to this email.

DERM Community | Derm for Primary Care Team